Home Drugs
Drugs
Can the arts be an effective tool to combat psychosis stigma?
There has been a rise in stigma for mental illnesses over the past few decades, particularly for psychotic symptoms. However, artistic representation may be the key to eliminating psychosis stigma.
The opioid crisis in canada – Governmental responses and strategies
Norm Buckley, Scientific Director at the Michael G. DeGroote Institute for Pain Research & Care, and Jason Busse, Director of the Michael G DeGroote National Pain Centre at McMaster University, discuss the complexities of chronic pain management and addressing the opioid crisis.
Who will staff the psychedelic resurgence?
Who will staff the psychedelic resurgence? Erika Dyck, Professor and Canada Research Chair in History of Health & Social Justice from the University of Saskatchewan, provides an intriguing answer to this question.
The extent and impact of the opioid crisis in Canada
The opioid crisis in Canada has been an issue for nearly a quarter of a century. Here, Norm Buckley and Jason Busse from the Michael G DeGroote Institute for Pain Research and Care, and the National Pain Centre discuss the issue, its effects both general and on specific communities, and what can be done about it.
Will psychedelic research and the ‘psychedelic renaissance’ create another generational divide?
Erika Dyck, Canada Research Chair in History of Health & Social Justice at the University of Saskatchewan, discusses changing attitudes to psychedelics and the challenges in forming a strong evidence base from available psychedelic research.
The role of prescribing practices in managing chronic pain with opioids
Norm Buckley and Jason Busse from the Michael G. DeGroote Institute for Pain Research and Care discuss prescribing practices, managing chronic pain with opioids, and the contribution of licit and illicit opioids towards the Canadian opioid crisis.
Psychotic-like experiences: What are they and why are they important?
Dr Lorna Staines and Professor Mary Cannon of RCSI University of Medicine and Health Sciences, explore psychotic-like experiences, explaining what they are and why they are important.
What is at stake in the psychedelic renaissance?
Professor Erika Dyck, Canada Research Chair in the History of Health & Social Justice, discusses the extensive history and growing medical application of psychedelics known as the psychedelic renaissance.
Exploring the effects of medical cannabis for chronic pain
Dr Simon Erridge of Sapphire Medical Clinics discusses the therapeutic effects of medical cannabis for chronic pain, affecting 15.5 million people in England and why more evidence is needed to support greater patient access.
Psychedelic therapies: The case for a new focus in the EU’s mental health care...
Tadeusz Hawrot, Founder and Executive Director of PAREA, states the case for a new focus in the EU’s mental health care approach, that is the underserved area of psychedelic therapies.
The history of psychedelics and why psychedelic stories matter
Erika Dyck delves into the history of psychedelics, exploring how these substances have piqued the interest and influenced the attitudes of individuals across academia, culture, and medicine.
Using of opioids for chronic pain: Controversies, guidelines, research needs
First in a series of five articles, Norm Buckley and Jason Busse explore the trials and tribulations associated with using opioids for chronic pain, particularly in Canada.
Neuronal networks of depression: Pushing the limits of brain stimulation technology
A team of researchers at the University of Freiburg and Delft University of Technology have joined forces to explore a new focused ultrasound technology to tap into the Neuronal Networks of Depression.
The global regulatory landscape for psychedelic drugs
Jessica Riggleman, Owner of Raeco, LLC, examines the global regulatory landscape for psychedelic drugs, with a particular focus on Schedule I classification.
Beyond amyloid: What’s next for Alzheimers disease therapeutics?
Bradlee Heckmann, PhD, from USF Health Neuroscience Institute, Byrd Alzheimer’s Center & Asha Therapeutics, in this discussion goes beyond amyloid, asking what’s next for Alzheimer’s Disease therapeutics.
Brain health conditions: Excellence in psychedelic treatments
Psychedelic treatments open up an unparalleled window of opportunity, but we need to get ready for their roll-out.
The fentanyl crisis: Death at the end of the rainbow
Chelsea Unkel, Ryan Hogans, & Pamela Lein from the University of California, Davis, analyse the fentanyl crisis responsible for increases in drug overdose across the US.
Evaluating a novel treatment for opioid use disorder based on dual-brain psychology and photobiomodulation
Dr. Fredric Schiffer, founder and CEO of MindLight, LLC, looks at treatments for opioid use disorder based on Dual-Brain Psychology and photobiomodulation. Dr. Schiffer is also a part-time assistant professor in psychiatry at Harvard Medical School.
Alzheimer’s drug slows memory decline in phase 3 trial
Henry Scowcroft from Alzheimer’s Research UK, argues that an Alzheimer’s drug, lecanemab, can slow memory decline in a phase 3 trial.
Tuberculosis drug regimens and their efficacies
Andrew Nunn, Professor of Epidemiology in the Medical Research Council Clinical Trials Unit at UCL, analyses tuberculosis drug development.
